Sareum Hldgs Plc (SAR) - Total Liabilities

Latest as of December 2025: GBX2.04 Million GBX ≈ $248.33 USD

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has total liabilities worth GBX2.04 Million GBX (≈ $248.33 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SAR long-term investment intensity to see how much of total assets are deployed in long-term investments.

Sareum Hldgs Plc - Total Liabilities Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SAR current and non-current assets.

Sareum Hldgs Plc Competitors by Total Liabilities

The table below lists competitors of Sareum Hldgs Plc ranked by their total liabilities.

Company Country Total Liabilities
Kromek Group PLC
LSE:KMK
UK GBX8.87 Million
Element Lifestyle Retirement Inc
V:ELM
Canada CA$2.09 Million
Kermode Resources Ltd
V:KLM
Canada CA$255.54K
Reliance Industries Limited
IL:RIGD
UK $10.92 Trillion
MAPLE LEAF GREEN WORLD
F:4HV0
Germany €12.35 Million
Oxford Metrics plc
LSE:OMG
UK GBX17.52 Million
TrustBIX Inc
V:TBIX
Canada CA$3.35 Million
S2Medical AB
ST:S2M
Sweden Skr7.03 Million

Liability Composition Analysis (2004–2025)

This chart breaks down Sareum Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sareum Hldgs Plc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.59 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.71 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.63 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sareum Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sareum Hldgs Plc (2004–2025)

The table below shows the annual total liabilities of Sareum Hldgs Plc from 2004 to 2025.

Year Total Liabilities Change
2025-06-30 GBX1.95 Million
≈ $237.62
+199.08%
2024-06-30 GBX653.00K
≈ $79.45
-24.68%
2023-06-30 GBX867.00K
≈ $105.49
+90.55%
2022-06-30 GBX455.00K
≈ $55.36
+60.12%
2021-06-30 GBX284.15K
≈ $34.57
+43.12%
2020-06-30 GBX198.54K
≈ $24.16
+35.13%
2019-06-30 GBX146.93K
≈ $17.88
-19.91%
2018-06-30 GBX183.46K
≈ $22.32
+17.95%
2017-06-30 GBX155.53K
≈ $18.92
+56.24%
2016-06-30 GBX99.55K
≈ $12.11
+47.61%
2015-06-30 GBX67.44K
≈ $8.21
+2.48%
2014-06-30 GBX65.81K
≈ $8.01
-17.66%
2013-06-30 GBX79.92K
≈ $9.72
-34.96%
2012-06-30 GBX122.87K
≈ $14.95
+26.67%
2011-06-30 GBX97.00K
≈ $11.80
0.00%
2010-06-30 GBX97.00K
≈ $11.80
+86.54%
2009-06-30 GBX52.00K
≈ $6.33
-88.15%
2008-06-30 GBX439.00K
≈ $53.41
-62.70%
2007-06-30 GBX1.18 Million
≈ $143.21
+102.93%
2006-06-30 GBX580.00K
≈ $70.57
+22.88%
2005-06-30 GBX472.00K
≈ $57.43
-41.73%
2004-06-30 GBX810.00K
≈ $98.55
--

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$505.78K
GBX4.16 Billion GBX
Market Cap Rank
#31063 Global
#927 in UK
Share Price
GBX30.00
Change (1 day)
+1.69%
52-Week Range
GBX12.00 - GBX37.00
All Time High
GBX457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more